Four primary pathophysiologic pathways are involved in the development of PAH: Endothelin-1 (ET-1), nitric oxide, prostacyclins and signaling mediated by the anti-proliferative bone morphogenetic protein receptor type II (BMPR-II) [24,25,26,27]. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.